Drug intelligence / Profile preview

K-76

Development stage: Preclinical
Lead developer: Taiho Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

K-76 is a complement inhibitor developed by Otsuka Pharmaceutical for the treatment of inflammatory bowel diseases, particularly active-stage ulcerative colitis. In clinical evaluation, K-76 demonstrated efficacy as monotherapy in patients with active ulcerative colitis and showed benefit in some cases of refractory disease when used alongside corticosteroids and salicylazosulphapyridine. Its mechanism involves inhibition of the complement system, which plays a role in inflammation associated with conditions like ulcerative colitis and Crohn's disease[6].

Targets

Beyond the preview

Go deeper on K-76.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on K-76.

Explore the full profile